BDMC33, A Curcumin Derivative Suppresses Inflammatory Responses in Macrophage-Like Cellular System: Role of Inhibition in NF-κB and MAPK Signaling Pathways
Our preliminary screening has shown that curcumin derivative BDMC33 [2,6-bis(2,5-dimethoxybenzylidene)cyclohexanone] exerted promising nitric oxide inhibitory activity in activated macrophages. However, the molecular basis and mechanism for its pharmacological action is yet to be elucidated. The aim of this study was to investigate the anti-inflammatory properties of BDMC33 and elucidate its underlying mechanism action in macrophage cells. Our current study demonstrated that BDMC33 inhibits the secretion of major pro-inflammatory mediators in stimulated macrophages, and includes NO, TNF-α and IL-1β through interference in both nuclear factor kappaB (NF-κB) and mitogen activator protein kinase (MAPK) signaling cascade in IFN-γ/LPS-stimulated macrophages. Moreover, BDMC33 also interrupted LPS signaling through inhibiting the surface expression of CD-14 accessory molecules. In addition, the inhibitory action of BDMC33 not only restricted the macrophages cell (RAW264.7), but also inhibited the secretion of NO and TNF-α in IFN-γ/LPS-challenged microglial cells (BV-2). The experimental data suggests the inflammatory action of BDMC33 on activated macrophage-like cellular systems, which could be used as a future therapeutic agent in the management of chronic inflammatory diseases.
References
[1]
Rodriguez-Vita, J.; Lawrence, T. The resolution of inflammation and cancer. Cytokine Growth Factor Rev 2010, 2, 61–65.
Bowdish, D.M.E.; Loffredo, M.S.; Mukhopadhyay, S.; Mantovani, A.; Gordon, S. Macrophage receptors implicated in the “adaptive” form of innate immunity. Microbes Infect 2007, 9, 1680–1687.
[4]
Chan, E.D.; Riches, D.W.H. IFN-γ + LPS induction of iNOS is modulated by ERK, JNK/SAPK, and p38mapk in a mouse macrophage cell line. Am. J. Physiol. Cell Physiol 2001, 280, 441–450.
[5]
Held, T.K.; WeiHua, X.; Yuan, L.; Kalvakolanu, D.V.; Cross, A.S. Gamma interferon uugments macrophage activation by lipopolysaccharide by two distinct mechanisms, at the signal transduction level and via an autocrine mechanism involving tumor necrosis factor alpha and interleukin-1. Infect. Immun 1999, 67, 206–212.
[6]
Dobrovolskaia, M.A.; Vogel, S.N. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect 2002, 4, 903–914.
[7]
Schroder, K.; Sweeta, M.J.; Hume, D.A. Signal integration between IFN-γ and TLR signaling pathways in macrophages. Immunobiology 2006, 211, 511–524.
Aktan, F. iNOS-mediated nitric oxide production and its regulation. Life Sci 2004, 75, 639–653.
[10]
Hofseth, L.J. Nitric oxide as a target of complementary and alternative medicines to prevent and treat inflammation and cancer. Cancer Lett 2008, 268, 10–30.
Christ-Crain, M.; Opal, S.M. The role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit. Care 2010, 14, 203–214.
[13]
Makarov, S.S. NF-kB as a therapeutic target in chronic inflammation: Recent advances. Mol. Med. Today 2000, 6, 441–448.
[14]
Li, Q.; Verma, I.M. NF-κB Regulation in the immune system. Nat. Rev. Immunol 2002, 2, 725–734.
[15]
Beauparlant, P.; John, H. Biological and Biochemical Inhibitors of the NF-KB/Rel Proteins and Cytokine Synthesis. Cytokine Growth Factor Rev 1996, 7, 175–190.
[16]
May, M.J.; Ghosh, S. Signal transduction through NF-kB. Immunol. Today 1998, 19, 80–88.
[17]
Roshak, A.K.; Callahan, J.F.; Blake, S.M. Small-molecule inhibitors of NF-κB for the treatment of inflammatory joint disease. Curr. Opin. Pharmacol 2002, 2, 316–321.
[18]
Gabby Krens, S.F.; Spaink, H.P.; Snaar-Jagalska, B.E. Functions of the MAPK family in vertebrate-development. FEBS Lett 2006, 580, 4984–4990.
Kim, E.K.; Choi, E. Pathological roles of MAPK signaling pathways in human diseases. Biochem. Biophys. Acta 2010, 1802, 396–405.
[21]
Anand, P.; Thomas, S.G.; Kunnumakkara, A.B.; Sundaram, C.; Harikumar, K.B.; Sung, B.; Tharakan, S.T.; Misra, K.; Priyadarsini, I.K.; Rajasekharan, K.N.; et al. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem. Pharmacol 2008, 76, 1590–1611.
[22]
Aggarwal, B.B.; Harikumar, B.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell B 2009, 41, 40–59.
[23]
Chathoth, S.; Thayyullathil, F.; Galadari, S. Curcumin cell signaling: A possible target for chemotherapy. Curr. Trends Biotechnol. Pharm 2008, 2, 226–238.
[24]
Liang, G.; Li, X.; Chen, L.; Yang, S.; Wu, X.; Studer, E.; Gurley, E.; Hylemon, P.B.; Ye, F.; Li, Y.; Zhou, H. Synthesis and anti-inflammatory activities of mono-carbonyl analogues of curcumin. Bioorg. Med. Chem. Lett 2008, 18, 1525–1529.
[25]
Lee, K.H.; Abd Aziz, F.H.; Syahida, A.; Abas, F.; Shaari, K.; Israf, D.A.; Lajis, N.H. Synthesis and biological evaluation of curcumin-like diarylpentanoid analogues for anti-inflammatory, antioxidant and anti-tyrosinase activities. Eur. J. Med. Chem 2009, 44, 3195–3200.
[26]
Pan, M.H.; Lin-Shiau, S.Y.; Lin, J.K. Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IκB kinase and NFκB activation in macrophages. Biochem. Pharmacol 2000, 60, 1665–1676.
[27]
Camacho-Barquero, L.; Villegas, I.; Sánchez-Calvo, J.M.; Talero, E.; Sánchez-Fidalgo, S.; Motilva, V.; Alarcón de la Lastra, C. Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathways modulating COX-2 and iNOS expression in chronic experimental colitis. Int. J. Immunopharm 2007, 7, 333–342.
[28]
Gafner, S.; Lee, S.K.; Cuendet, M.; Barthelemy, S.; Vergnes, L.; Labidalle, S.; Mehta, R.; Boone, D.W.; Pezzuto, J.M. Biologic evaluation of curcumin and structural derivatives in cancer chemoprevention model systems. Phytochemistry 2004, 65, 2849–2859.
Alten, R.; Gram, H.; Joosten, L.A.; van der Berg, W.B.; Sieper, J.; Wassenberg, S.; Burmester, G.; Riel, P.V.; Diaz-Lorente, M.; Bruin, G.L.M.; et al. The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res. Ther 2008, 10, R67–R76.
[31]
Moon, D.O.; Kim, M.O.; Choi, Y.H.; Park, Y.M.; Kim, G.Y. Cucurmin attenuates inflammatory response in IL-1β-induced human synovial fibroblast and collagen-induced arthritis in mouse model. Int. J. Immunopharm 2010, 10, 605–610.
[32]
Kleinert, H.; Pautz, A.; Linker, K.; Schwarz, P.M. Regulation of the expression of inducible nitric oxide synthase. Eur. J. Pharmacol 2004, 500, 255–266.
[33]
Liu, H.; Sidiropoulos, P.; Song, G.; Pagliari, L.J.; Birrer, M.J.; Stein, B.; Anrather, J.; Pope, R.M. TNF-α gene expression in macrophages: Regulation by NF-κB is independent of c-Jun or C/EBPβ. J. Immunol 2000, 164, 4277–4285.
[34]
Zhang, Y.; Saccani, S.; Shin, H.; Nikolajczyk, B.S. Dynamic protein associations define two phases of IL-1β transcriptional activation. J. Immunol 2008, 181, 503–512.
[35]
Jung, K.K.; Lee, H.S.; Cho, J.Y.; Shin, W.C.; Rhee, M.H.; Kim, T.G.; Kang, J.H.; Kim, S.H.; Hong, S.; Kang, S.Y. Inhibitory effect of curcumin on nitric oxide production from lipopolysaccharide-activated primary microglia. Life Sci 2006, 79, 2022–2031.
Kamijo, R.; Harada, H.; Matsuyama, T.; Bosland, M.; Gerecitano, J.; Shapiro, D.; Le, J.; Koh, S.I.; Kimura, T.; Green, S.J. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 1994, 263, 1612–1615.
[38]
Guo, Z.; Shao, L.; Feng, X.; Reid, K.; Marderstein, E.; Nakao, A.; Geller, D.A. A critical role for C/EBPβ binding to the AABS promoter response element in the human iNOS gene. FASEB J 2003, 17, 1718–1720.
[39]
Rossi, A.; Kapahi, P.; Natoli, G.; Takahashi, T.; Chen, Y.; Karin, M.; Santoro, M.G. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 2000, 403, 103–118.
[40]
Reynaert, N.L.; Ckless, K.; Korn, S.H.; Vos, N.; Guala, A.S.; Wouters, E.F.M.; van der Vliet, A.; Janssen-Heininger, Y.M. Nitric oxide represses inhibitory kappaB kinase through S-nitrosylation. Proc. Natl. Acad. Sci. USA 2004, 101, 8945–8950.
[41]
Kapahi, P.; Takahashi, T.; Natoli, G.; Adams, S.R.; Chen, Y.; Tsien, R.Y.; Karin, M. Inhibition of NF-κB activation by arsenite through reaction with a critical cysteine in the activation loop of IkB kinase. J. Biol. Chem 2000, 275, 36062–36066.
[42]
Jeon, K.I.; Byun, M.S.; Jue, D.M. Gold compound auranofin inhibits IκB kinase (IKK) by modifying Cys-179 of IKKβ subunit. Exp. Mol. Med 2003, 35, 61–66.
[43]
Conroy, J.L.; Seto, C.T. Demonstration by 13C NMR Studies that tetrahydropyranone-based inhibitors bind to cysteine proteases by reversible formation of a hemithioketal adduct. J. Org. Chem 1998, 63, 2367–2370.
[44]
Bonvina, C.; Guillona, A.; van Bemmelena, M.X.; Gerwinsb, P.; Johnsonc, G.L.; Widmann, C. Role of the amino-terminal domains of MEKKs in the activation of NFκB and MAPK pathways and in the regulation of cell proliferation and apoptosis. Cell Signal 2002, 14, 123–131.
[45]
Zhao, Q.; Lee, F.S. Mitogen-activated protein kinase/ERK kinase kinases 2 and 3 activate nuclear factor-κB through IκB kinase-α and IκB kinase-β. J. Org. Chem 1999, 274, 8355–8358.
[46]
Xue, F.; Seto, C.T. A comparison of cyclohexanone and tetrahydro-4H-thiopyran-4-one 1,1-dioxide as pharmacophores for the design of peptide-based inhibitors of the serine protease plasmin. J. Org. Chem 2005, 70, 8309–8321.
[47]
Palusiaka, M.; Grabowski, S.J. Methoxy group as an acceptor of proton in hydrogen bonds. J. Mol. Struct 2002, 642, 97–104.
[48]
Pae, H.O.; Jeong, S.O.; Kim, H.S.; Kim, S.H.; Song, Y.S.; Kim, S.K.; Chai, K.Y.; Chung, H.T. Dimethoxycurcumin, a synthetic curcumin analogue with higher metabolic stability, inhibits NO production, inducible NO synthase expression and NF-kappaB activation in RAW264.7 macrophages activated with LPS. Mol. Nutr. Food Res 2008, 52, 1082–1091.
[49]
Thorgersen, E.B.; Hellerud, B.C.; Nielsen, E.W.; Barratt-Due, A.; Fure, H.; Lindstad, J.K.; Pharo, A.; Fosse, E.; T？nnessen, T.I.; Johansen, H.T.; et al. CD14 inhibition efficiently attenuates early inflammatory and hemostatic responses in Escherichia coli sepsis in pigs. FASEB J 2010, 24, 712–722.
[50]
Genth-Zotz, S.; von Haehling, S.; Bolger, A.P.; Kalra, P.R.; Wensel, R.; Coats, A.J.S.; Volk, H.D.; Anker, S.D. The anti-CD14 antibody IC14 suppresses ex vivo endotoxin stimulated tumor necrosis factor-alpha in patients with chronic heart failure. Eur. J. Heart Fail 2006, 8, 366–372.
[51]
Verbon, A.; Dekkers, P.E.P.; Hove, T.T.; Hack, C.E.; Pribble, J.P.; Turner, T.; Souza, S.; Axtelle, T.; Hoek, F.J.; van Deventer, S.J.H.; et al. IC14, an Anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J. Immunol 2001, 166, 3599–3605.
[52]
Mir, M.; Tolosa, L.; Asensio, V.J.; Lladó, J.; Olmos, G. Complementary roles of tumor necrosis alpha and interferon gamma in inducible microglial nitric oxide generation. J. Neuroimmunol 2008, 204, 101–109.
[53]
Wang, M.J.; Kuo, J.S.; Lee, W.W.; Huang, H.Y.; Chen, W.F.; Lin, S.Z. Translational event mediates differential production of tumor necrosis factor-alpha in hyaluronan-stimulated microglia and macrophages. J. Neurochem 2006, 97, 857–871.
[54]
Watters, J.J.; Sommer, J.A.; Pfeiffer, Z.A.; Prabhu, U.; Guerra, A.N.; Bertics, P.J. A differential role for the mitogen activated protein kinases in lipopolysaccharide signaling: The MEK/ERK pathway is not essential for nitric oxide and interleukin 1β production. J. Biol. Chem 2002, 277, 9077–9087.
